HTF Market Intelligence released a new research report of 186 pages on title ‘Uveitis – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
Uveitis – Pipeline Review, H1 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Uveitis – Pipeline Review, H1 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.
Request a sample report @ https://www.htfmarketreport.com/sample-report/398233-uveitis-pipeline-review
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Uveitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 5, 2, 29, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
2-BBB Medicines BV
Aldeyra Therapeutics Inc
Apitope International NV
Astellas Pharma Inc
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
Enzo Biochem Inc
EyeGate Pharmaceuticals Inc
- Hoffmann-La Roche Ltd
HanAll Biopharma Co Ltd
Icon Bioscience Inc
Idera Pharmaceuticals Inc
InnoMedica Holding AG
KPI Therapeutics Inc
Midatech Pharma Plc
Nemus Bioscience Inc
Orchid Pharma Ltd
Palatin Technologies Inc
Panacea Biotec Ltd
Panoptes Pharma GesmbH
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
Santen Pharmaceutical Co Ltd
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/398233-uveitis-pipeline-review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Global Markets Direct Report Coverage 7
Uveitis – Overview 8
Uveitis – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Uveitis – Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Uveitis – Companies Involved in Therapeutics Development 30
2-BBB Medicines BV 30
Aciont Inc 30
Aldeyra Therapeutics Inc 31
Apitope International NV 31
Astellas Pharma Inc 32
Bionomics Ltd 32
Bristol-Myers Squibb Company 33
Can-Fite BioPharma Ltd 33
Clearside BioMedical Inc 34
Coherus BioSciences Inc 34
Elasmogen Ltd 35
Endocyte Inc 35
Enzo Biochem Inc 36
EyeGate Pharmaceuticals Inc 36
Eyevensys SAS 37
- Hoffmann-La Roche Ltd 37
HanAll Biopharma Co Ltd 38
Icon Bioscience Inc 38
Idera Pharmaceuticals Inc 39
InnoMedica Holding AG 39
KPI Therapeutics Inc 40
Midatech Pharma Plc 40
Mitotech SA 41
Nemus Bioscience Inc 41
Neuroptis Biotech 42
Novartis AG 42
Oculis ehf 43
OncoNOx ApS 43
Orchid Pharma Ltd 44
OSE Immunotherapeutics 44
Palatin Technologies Inc 45
Panacea Biotec Ltd 45
Panoptes Pharma GesmbH 46
Pfizer Inc 46
pSivida Corp 47
Re-Pharm Ltd 47
Regeneron Pharmaceuticals Inc 48
Sandoz International GmbH 48
Santen Pharmaceutical Co Ltd 49
SynDevRx Inc 49
TxCell SA 50
Uveitis – Drug Profiles 51
2B-3201 – Drug Profile 51
abatacept – Drug Profile 53
adalimumab biosimilar – Drug Profile 60
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/398233-uveitis-pipeline-review
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=398233
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218